Online inquiry

IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12092MR)

This product GTTS-WQ12092MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12092MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15766MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ4615MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ6045MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ7236MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ1438MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ4353MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ11195MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ5155MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW